More patients receiving MOUNJARO 5 mg (3.0%), MOUNJARO 10 mg (5.4%), and MOUNJARO 15 mg (6.6%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%)
Comparing Wegovy With Other GLP-1s on Weight Loss Potential Wegovy generally results in more significant weight loss than Ozempic or Trulicity
For people with diabetes, this combo can increase the risk of hypoglycemia a serious drop in blood sugar that can cause symptoms like dizziness, shakiness, sweating, confusion, and fainting
Jastreboff AM, Aronne LJ, Ahmad NN, et al
Conclusion Mounjaro (Tirzepatide) is a promising treatment for Type 2 Diabetes and obesity, offering better blood sugar control and weight loss benefits